Enbezotinib

Enbezotinib is a small molecule inhibitor that is currently under investigation for its potential use in the treatment of various types of cancer. It is a selective inhibitor of the MET oncogene, which is often overexpressed or mutated in many types of cancer.

Mechanism of Action

Enbezotinib works by selectively inhibiting the MET oncogene. The MET oncogene encodes for a tyrosine kinase receptor that, when overexpressed or mutated, can lead to uncontrolled cell growth and proliferation, a hallmark of cancer. By inhibiting this receptor, enbezotinib can potentially slow down or stop the growth of cancer cells.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of enbezotinib in various types of cancer. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and improved survival rates. However, more research is needed to fully understand the potential benefits and risks of this treatment.

Side Effects

Like all chemotherapy drugs, enbezotinib can cause side effects. These can include nausea, vomiting, fatigue, and hair loss. More serious side effects can include liver damage, heart problems, and an increased risk of infection due to a weakened immune system.

Future Directions

Research is ongoing to further understand the potential of enbezotinib in cancer treatment. This includes exploring its use in combination with other treatments, as well as investigating its efficacy in different types of cancer.

See Also

• Cancer
• Chemotherapy
• Clinical trial
• MET
• Small molecule inhibitor
• Tyrosine kinase receptor